他汀类药物在自发性脑出血中的神经保护作用
本文综述了他汀类药物在自发性脑出血中潜在神经保护作用的机制与临床证据。临床前研究一致显示他汀可改善神经功能、减轻脑水肿并促进血肿清除,回顾性临床研究报告其与降低死亡率及改善功能结局相关。但既往随机试验亚组分析提示既往出血性卒中患者使用他汀可能增加再出血风险,多数他汀试验未显示出血性卒中风险增加,尚需前瞻性试验验证。
要点
- 他汀可能通过下调甲羟戊酸通路靶向脑出血后继发性脑损伤。
- 临床前研究显示他汀改善神经功能、减轻水肿并促进血肿清除。
- 回顾性研究提示他汀与降低死亡率和改善功能结局相关,但需前瞻性验证。
核心结论
- 他汀在自发性脑出血中可能具有神经保护作用,但现有证据主要来自临床前和回顾性研究,尚需前瞻性试验验证其对脑出血后结局的影响。
研究设计与样本
- 本文为综述,汇总了临床前研究、回顾性临床研究及既往随机试验亚组分析中关于他汀与自发性脑出血关系的证据。
主要发现
- 临床前研究一致显示他汀具有神经保护和促进恢复的作用,包括改善神经功能、减少脑水肿、增加血管新生和神经发生、加速血肿清除及减少炎症细胞浸润。
- 回顾性临床研究报告,脑出血前服用他汀的患者血肿周围水肿减少、死亡率降低且功能结局改善。
- 若干临床研究观察到脑出血后继续或起始他汀治疗的患者死亡率降低且功能结局改善。
- 既往随机试验的亚组分析提示,既往出血性卒中患者使用他汀可能与再出血风险升高相关。
- 多数他汀试验未显示他汀使用与出血性卒中风险增加相关。
临床怎么用
- 对于脑出血前已服用他汀的患者,现有回顾性证据提示继续使用可能与更好的功能结局相关,但需结合个体再出血风险评估。
- 对于既往有出血性卒中史的患者,启用他汀时应关注亚组分析提示的再出血风险信号。
局限性
- 他汀剂量不一致、脑出血前他汀使用情况差异以及选择偏倚限制了对脑出血后结局的严谨研究。
- 现有证据多为临床前和回顾性研究,缺乏前瞻性试验验证他汀与脑出血后结局的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Statins, a common drug class for treatment of dyslipidemia, may be neuroprotective for spontaneous intracerebral hemorrhage (ICH) by targeting secondary brain injury pathways in the surrounding brain parenchyma. Statin-mediated neuroprotection may stem from downregulation of mevalonate and its derivatives, targeting key cell signaling pathways that control proliferation, adhesion, migration, cytokine production, and reactive oxygen species generation. Preclinical studies have consistently demonstrated the neuroprotective and recovery enhancement effects of statins, including improved neurologic function, reduced cerebral edema, increased angiogenesis and neurogenesis, accelerated hematoma clearance, and decreased inflammatory cell infiltration. Retrospective clinical studies have reported reduced perihematomal edema, lower mortality rates, and improved functional outcomes in patients who were taking statins before ICH. Several clinical studies have also observed lower mortality rates and improved functional outcomes in patients who were continued or initiated on statins after ICH. Subgroup analysis of a previous randomized trial has raised concerns of a potentially elevated risk of recurrent ICH in patients with previous hemorrhagic stroke who are administered statins. However, most statin trials failed to show an association between statin use and increased hemorrhagic stroke risk. Variable statin dosing, statin use in the pre-ICH setting, and selection biases have limited rigorous investigation of the effects of statins on post-ICH outcomes. Future prospective trials are needed to investigate the association between statin use and outcomes in ICH.
引用
- Chen CJ, Ding D, Ironside N, et al. Statins for neuroprotection in spontaneous intracerebral hemorrhage. Neurology. 2019. PMID: 31712367. doi:10.1212/WNL.0000000000008627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。